Phoenix Molecular Designs Announces New Preclinical Data for Targeted Triple Negative Breast Cancer (TNBC) Therapy

 May 25, 2017 - VANCOUVER, British Columbia and SAN DIEGO.  Our latest preclinical study results show that our lead compound PMD-026 demonstrates 70% inhibition of ribosomal S6 kinase (RSK) signaling, blocking TNBC tumor growth and with no adverse effects in mice. 

Read the full press release here